Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428367 | 0.92 | HPGD (0.47) | HPGDRAB9ANPC1TP53HTT | |
| SCHEMBL6314813 | 0.87 | RAB9A (0.49) | HPGDRAB9ANPC1TP53HTT | |
| SCHEMBL6312734 | 0.87 | NR4A3 (0.49) | ALDH1A1MAPK14MAPTGAAMAPK1 | |
| SCHEMBL6312727 | 0.86 | TP53 (0.52) | HPGDRAB9ANPC1TP53HTT | |
| SCHEMBL6319072 | 0.84 | NPC1 (0.46) | HPGDRAB9ANPC1TP53HTT | |
| SCHEMBL4452242 | 0.82 | SLC9A1 (0.48) | RAB9ATP53SMN1; SMN2ALDH1A1MAPK14 | |
| SCHEMBL4452237 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPK14MAPTGAAMAPK1 | |
| SCHEMBL2326321 | 0.79 | ALDH1A1 (0.68) | HPGDRAB9AHTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6313370 | 0.78 | NR4A3 (0.61) | RAB9ATP53HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6313388 | 0.78 | SLC9A1 (0.53) | HPGDRAB9ANPC1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | HPGD 33/4885RAB9A 2117/4885NPC1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.